More on PCRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $26.60 |
|
|||
| Open | $26.38 | ||||
| 52 Wk High | $80.25 | ||||
| 52 Wk Low | $30.25 | ||||
| Day High | $26.65 | ||||
| Day Low | $26.31 | ||||
| P/E | N/A | ||||
| EPS | $-2.08 | ||||
| Volume | 481,690 | ||||
- PharmaCorp Rx Inc. Announces Board and Committee Changes
- PharmaCorp Rx Inc. Announces Second Quarter 2026 Financial Results
- Form 4 Pacira BioSciences, Inc. For: Aug 17 Filed by: SLONIN JONATHAN
- Form 144 Pacira BioSciences, Inc. Filed by: SLONIN JONATHAN
- Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
- Form SCHEDULE 13G Pacira BioSciences, Inc. Filed by: STATE STREET CORP
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pacira publishes two-year Phase 1 data for knee OA gene therapy
- Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
- Pacira Pharmaceuticals (PCRX) PT Raised to $25 at RBC Capital
Entities mentioned with PCRX
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Stock Buyback | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
